Saturday 17 October 2026
Export CRMD’s income statement to Excel — free account
CorMedix Inc
CRMD Healthcare Biotechnology
CorMedix Inc’s revenue for fiscal 2025 (year ended December 2025) was $311.7 million, up 617.0% from fiscal 2024. In the quarter to June 2026, revenue grew 156.5%, EPS grew 13.8% and free cash flow grew 185.9%, each against the same quarter a year earlier.
7.26
0.20
−2.68%
Follow CRMD
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | 4 | 3 | 4 | 5 | 4 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 5.26 |
Altman Z-Score |
(1.85) | (20.62) | (12.34) | 7.43 | 18.12 | 11.40 | 7.80 | — | 4.93 | 2.15 |
P/S ratio |
289.71 | 88.72 | 267.37 | 620.64 | 887.19 | 897.28 | 2,574.09 | — | 10.96 | 2.69 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 4.85 |
Altman Z″-Score (non-manufacturers) |
(15.45) | (48.70) | (36.41) | (16.91) | (3.10) | 2.06 | (3.87) | — | (3.52) | 3.07 |
Beneish M-Score |
— | (2.99) | (0.03) | — | — | 11.52 | — | — | — | 12.80 |
P/Operating CF |
(9.99) | (4.02) | (15.96) | (45.26) | (35.77) | (29.20) | (27.35) | — | (84.93) | 8.87 |
P/B ratio |
3.64 | 4.06 | 23.29 | 7.44 | 4.80 | 2.73 | 3.06 | — | 5.63 | 2.07 |
Price to Tangible BV |
3.64 | 4.06 | 23.29 | 7.44 | 4.80 | 2.73 | 3.06 | — | 5.76 | 0.00 |
EV/Sales |
198.96 | 51.82 | 240.22 | 519.95 | 696.40 | 558.04 | 1,683.43 | — | 9.79 | 2.68 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 5.04 |
EV/Operating CF |
(2.00) | (0.60) | (4.36) | (9.79) | (7.58) | (5.04) | (4.52) | — | (8.41) | 4.76 |
EV/FCF |
(2.00) | (0.59) | (4.35) | (9.76) | (7.54) | (4.72) | (4.48) | — | (8.39) | 4.83 |
Quick Ratio |
4.97 | 1.95 | 2.29 | 4.90 | 11.19 | 12.28 | 9.34 | 6.68 | 3.05 | 1.83 |
Current Ratio |
5.34 | 2.12 | 2.40 | 5.04 | 11.58 | 12.44 | 9.44 | 6.97 | 3.39 | 2.11 |
Net Debt/EBITDA |
0.82 | 0.37 | 0.44 | 1.38 | 1.69 | 2.21 | 1.92 | 1.56 | 2.36 | (0.02) |
Debt/Assets |
0.00% | 0.00% | 32.54% | 0.01% | 1.87% | 1.16% | 1.08% | 0.00% | 0.00% | 17.58% |
Debt/Equity |
0.00 | 0.00 | 1.24 | 0.00 | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 | 0.36 |
Asset Turnover |
0.01 | 0.02 | 0.03 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.43 | 0.66 |
Operating CF/Net income |
0.90 | 0.87 | 0.88 | 0.35 | 1.00 | 0.75 | 0.82 | 0.83 | 2.82 | 1.07 |
Capex/Depreciation |
(2.29) | (4.12) | (0.66) | (0.09) | (0.69) | (8.05) | (1.05) | (1.59) | (0.25) | (0.15) |
Interest Coverage |
(19,046.85) | (5,879.30) | (14,139.05) | (26.68) | (819.90) | (1,851.42) | (1,155.62) | (1,427.34) | (621.00) | 53.97 |
| (95.10%) | (264.01%) | (442.49%) | (304.66%) | (64.91%) | (52.72%) | (50.40%) | (74.02%) | (23.17%) | 66.56% | |
| (83.53%) | (186.71%) | (166.23%) | (180.27%) | (55.92%) | (47.71%) | (45.35%) | (64.32%) | (17.85%) | 34.51% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (42.38%) | 23.34% |
Return on Tangible Assets |
(138.37%) | (458.89%) | (242.59%) | (184.13%) | (49.91%) | (45.07%) | (54.15%) | (66.28%) | (21.72%) | 82.04% |
Average Days of Receivables |
19.54 | 71.05 | 9.26 | 0.00 | 5.19 | 86.80 | 0.00 | — | 433.70 | 200.51 |
Research and Development Expense of Revenue |
7,021.55% | 7,435.80% | 4,379.36% | 3,901.48% | 5,592.47% | 6,879.52% | 16,329.66% | 0.00% | 9.07% | 6.20% |
Selling, General and Administrative Expense of Revenue |
3,963.90% | 2,627.51% | 1,878.71% | 3,482.17% | 5,801.80% | 8,562.91% | 30,590.37% | 0.00% | 135.02% | 34.09% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.50 |
Share Based Compensation of Revenue |
595.81% | 503.83% | 258.40% | 861.14% | 1,045.07% | 2,641.49% | 6,222.48% | 0.00% | 14.10% | 4.44% |
Graham Net Nets |
0.27 | 0.24 | 0.04 | 0.13 | 0.20 | 0.35 | 0.31 | — | 0.17 | (0.06) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 16.73 |
Earnings Yield |
(37.43%) | (115.09%) | (25.58%) | (9.33%) | (10.23%) | (16.26%) | (17.70%) | — | (4.07%) | 19.00% |
Free Cash Flow Yield |
(34.39%) | (98.34%) | (20.67%) | (8.58%) | (10.40%) | (13.18%) | (14.60%) | — | (10.64%) | 20.62% |
Revenue per Share |
0.03 | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.74 | 4.33 |
Operating CF per Share |
(2.93) | (2.59) | (1.33) | (0.62) | (0.77) | (0.56) | (0.60) | (0.75) | (0.86) | 2.43 |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | 0.00 | (0.04) | (0.01) | (0.01) | 0.00 | (0.03) |
Free Cash Flow per Share |
(2.94) | (2.61) | (1.33) | (0.62) | (0.77) | (0.60) | (0.61) | (0.76) | (0.86) | 2.40 |
Cash per Share |
2.68 | 1.10 | 1.00 | 1.18 | 1.63 | 1.74 | 1.46 | 1.50 | 0.88 | 2.06 |
Shareholders Equity per Share |
2.35 | 0.65 | 0.28 | 0.98 | 1.55 | 1.67 | 1.37 | 1.38 | 1.44 | 5.63 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.35 | 0.65 | 0.28 | 0.98 | 1.55 | 1.67 | 1.37 | 1.38 | 1.44 | 5.63 |
Free Cash Flow |
(22.32) | (28.74) | (23.75) | (15.09) | (22.08) | (22.58) | (24.58) | (38.74) | (50.73) | 172.79 |
Working Capital |
17.74 | 7.01 | 10.90 | 23.52 | 44.02 | 61.12 | 53.24 | 68.05 | 80.74 | 192.78 |
Capital Expenditures |
(0.06) | (0.15) | (0.05) | (0.04) | (0.11) | (1.43) | (0.22) | (0.33) | (0.12) | (2.26) |
Net Current Asset Value |
17.74 | 7.01 | 4.77 | 23.52 | 43.10 | 60.32 | 52.57 | 67.53 | 80.39 | (53.78) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 5.55 |
Capex to Sales |
0.26 | 0.46 | 0.11 | 0.13 | 0.47 | 7.47 | 3.35 | 0.00 | 0.00 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 5.58 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.37 | 0.20 | 0.46 | 3.16 | 1.46 | 0.12 | 0.13 | 0.11 | 0.25 | 2.58 |
Cash ROIC |
(58.51%) | (148.53%) | (82.31%) | (28.92%) | (24.08%) | (17.48%) | (21.44%) | (26.49%) | (37.21%) | 24.72% |
Accounts Receivable Turnover |
1.37 | 8.65 | 11.46 | 51.98 | 140.71 | 7.82 | 0.00 | — | 1.68 | 2.80 |
Accounts Payable Turnover |
0.22 | 0.07 | 0.18 | 0.21 | 0.19 | 0.09 | 0.00 | 0.00 | 1.06 | 7.49 |
Inventory Turnover |
1.35 | 0.30 | 0.78 | 0.97 | 0.85 | 2.03 | 0.00 | 0.00 | 0.66 | 1.93 |
Average Days of Payables |
1,637.67 | 5,739.39 | 2,381.51 | 1,001.79 | 2,010.53 | 5,416.41 | 217,234.19 | 0.00 | 196.80 | 80.02 |
Days of Inventory on Hand |
165.93 | 1,885.94 | 394.16 | 331.06 | 255.93 | 7.35 | 0.00 | 0.00 | 869.59 | 301.61 |
Average Receivables |
0.16 | 0.04 | 0.04 | 0.01 | 0.00 | 0.02 | — | — | 25.85 | 111.44 |
Average Payables |
1.68 | 1.73 | 2.20 | 1.81 | 1.08 | 1.67 | 2.21 | 3.24 | 3.00 | 4.80 |
Average Inventory |
0.27 | 0.38 | 0.51 | 0.38 | 0.24 | 0.07 | — | 1.05 | 4.85 | 18.66 |
Average Assets |
29.50 | 17.68 | 16.14 | 24.15 | 39.39 | 59.13 | 65.49 | 72.05 | 100.45 | 472.49 |
Average Common Equity |
25.91 | 12.50 | 6.06 | 14.29 | 33.93 | 53.51 | 58.93 | 62.60 | 77.40 | 244.98 |
Columns are period end dates